Research and Markets has announced the addition of the "Melanoma Pipeline Highlights - 2017" drug pipelines to their offering.

Melanoma Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Melanoma market. It covers emerging therapies for Melanoma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Melanoma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Melanoma pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Melanoma pipeline products by the company.

Short-term Launch Highlights:

Find out which Melanoma pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Melanoma Pipeline by Stages

2. Melanoma Pipeline by Drug Class

3. Melanoma Pipeline by Company

4. Melanoma Phase 3 Clinical Trial Insights

5. Melanoma Phase 2 Clinical Trial Insights

6. Melanoma Phase 1 Clinical Trial Insights

7. Melanoma Preclinical Research Insights

8. Melanoma Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/dx9vgg/melanoma_pipeline